Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome

Digestive and Liver Disease

Volumn 47, Issue 3, 2015, Pages 181-190

  Lonardo, Amedeo ^a   Ballestri, Stefano ^d   Marchesini, Giulio ^b   Angulo, Paul ^c   Loria, Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b AUSL Modena   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Dissociation; Insulin resistance; Natural history; Pathogenesis

Indexed keywords

AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AMINOTRANSFERASE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DNA POLYMORPHISM; ENDOPLASMIC RETICULUM; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LONGITUDINAL STUDY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; DIABETES MELLITUS, TYPE 2; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY;

CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; LIVER; LONGITUDINAL STUDIES; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84923918979     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.09.020     Document Type: Review

References (234)

1. Angulo P. Non-alcoholic fatty liver disease. New England Journal of Medicine 2002, 346:1221-1231.
2. Marchesini G., Marzocchi R. Metabolic syndrome and NASH. Clinics in Liver Disease 2007, 11:105-117.
3. Nascimbeni F., Pais R., Bellentani S., et al. From NAFLD in clinical practice to answers from guidelines. Journal of Hepatology 2013, 59:859-871.
4. Caldwell S.H., Crespo D.M. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. Journal of Hepatology 2004, 40:578-584.
5. van der Poorten D., Samer C.F., Ramezani-Moghadam M., et al. Hepatic fat loss in advanced non-alcoholic steatohepatitis: are alterations in serum adiponectin the cause?. Hepatology 2013, 57:2180-2188.
6. Lonardo A., Sookoian S., Chonchol M., et al. Cardiovascular and systemic risk in non-alcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Current Pharmaceutical Design 2013, 19:5177-5192.
7. Skelly M.M., James P.D., Ryder S.D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. Journal of Hepatology 2001, 35:195-199.
8. Lonardo A., Caldwell S.H., Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology & Metabolism 2010, 5:403-423.
9. Wong R.J., Cheung R., Ahmed A. Non-alcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology 2014, 59:2188-2195.
10. Palaniappan L., Carnethon M.R., Wang Y., et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004, 27:788-793.
11. Eckel R.H. The metabolic syndrome. Lancet 2010, 375:181-183.
12. Haller H. Epidemiology and associated risk factors of hyperlipoproteinemia. Zeitschrift fur Die Gesamte Innere Medizin und Ihre Grenzgebiete 1977, 32:124-128.
13. Musso G., Gambino R., Bo S., et al. Should non-alcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008, 31:562-568.
14. Ferrannini E. Metabolic syndrome: a solution in search of a problem. Journal of Clinical Endocrinology and Metabolism 2007, 92:396-398.
15. Mottillo S., Filion K.B., Genest J., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. Journal of the American College of Cardiology 2010, 56:1113-1132.
16. Rachas A., Raffaitin C., Barberger-Gateau P., et al. Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study. Heart 2012, 98:650-655.
17. Kawada T. Predictors of the development of metabolic syndrome in male workers: a 3-year follow-up study. Journal of Occupational and Environmental Medicine 2012, 54:292-295.
18. Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. American Journal of Medicine 2006, 119:812-819.
19. Welzel T.M., Graubard B.I., Zeuzem S., et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011, 54:463-471.
20. Lonardo A. Fatty liver and non-alcoholic steatohepatitis. Where do we stand and where are we going?. Digestive Diseases 1999, 17:80-89.
21. Marchesini G., Brizi M., Morselli-Labate A.M., et al. Association of non-alcoholic fatty liver disease with insulin resistance. American Journal of Medicine 1999, 107:450-455.
22. Cortez-Pinto H., Camilo M.E., Baptista A., et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clinical Nutrition 1999, 18:353-358.
23. Vanni E., Bugianesi E., Kotronen A., et al. From the metabolic syndrome to NAFLD or vice versa?. Digestive and Liver Disease 2010, 42:320-330.
24. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology & Hepatology 2013, 10:330-344.
25. Machado M.V., Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Review of Gastroenterology & Hepatology 2014, 8:487-500.
26. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. The Lancet Diabetes & Endocrinology 2014, 2:901-910.
27. Lonardo A., Trande P. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. Journal of Gastroenterology and Hepatology 2000, 15:775-782.
28. Marchesini G., Brizi M., Bianchi G., et al. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
29. Jimba S., Nakagami T., Takahashi M., et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic Medicine 2005, 22:1141-1145.
30. Wong V.W., Hui A.Y., Tsang S.W., et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2006, 24:1215-1222.
31. Gastaldelli A., Kozakova M., Højlund K., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49:1537-1544.
32. Speliotes E.K., Massaro J.M., Hoffmann U., et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010, 51:1979-1987.
33. Kim S.H., Lee J.W., Hwang H.J. Associations between combinations of body mass index plus non-alcoholic fatty liver disease and diabetes mellitus among Korean adults. Asia Pacific Journal of Clinical Nutrition 2011, 20:14-20.
34. Bedogni G., Gastaldelli A., Manco M., et al. Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children. Nutrition, Metabolism and Cardiovascular Diseases 2012, 22:120-126.
35. Ortiz-Lopez C., Lomonaco R., Orsak B., et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with non-alcoholic fatty liver disease (NAFLD). Diabetes Care 2012, 35:873-878.
36. Porter S.A., Pedley A., Massaro J.M., et al. Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology 2013, 33:139-146.
37. Lazo M., Hernaez R., Eberhardt M.S., et al. Prevalence of non-alcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. American Journal of Epidemiology 2013, 178:38-45.
38. Li X., Xia M., Ma H., et al. Liver fat content, evaluated through semi-quantitative ultrasound measurement, is associated with impaired glucose profiles: a community-based study in Chinese. PLOS ONE 2013, 8:e65210.
39. Ou H.Y., Wang C.Y., Yang Y.C., et al. The association between non-alcoholic fatty pancreas disease and diabetes. PLOS ONE 2013, 8:e62561.
40. Loria P., Lonardo A., Anania F. Liver and diabetes. A vicious circle. Hepatology Research 2013, 43:51-64.
41. Musso G., Gambino R., Cassader M., et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine 2011, 43:617-649.
42. Ikai E., Noborizaka Y., Tsuritani I., et al. Serum gamma-glutamyl transpeptidase levels and hypertension in non-drinkers: a possible role of fatty liver in the pathogenesis of obesity related hypertension. Obesity Research 1993, 1:469-474.
43. Donati G., Stagni B., Piscaglia F., et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004, 53:1020-1023.
44. Lonardo A., Bellini M., Tartoni P., et al. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Italian Journal of Gastroenterology and Hepatology 1997, 29:351-356.
45. Knobler H., Schattner A., Zhornicki T., et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 1999 Feb, 92:73-79.
46. Marchesini G., Avagnina S., Barantani E.G., et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. Journal of Endocrinological Investigation 2005, 28:333-339.
47. Fan J.G., Zhu J., Li X.J., et al. Fatty liver and the metabolic syndrome among Shanghai adults. Journal of Gastroenterology and Hepatology 2005, 20:1825-1832.
48. Kotronen A., Westerbacka J., Bergholm R., et al. Liver fat in the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2007, 92:3490-3497.
49. Kawamoto R., Kohara K., Tabara Y., et al. Serum gamma-glutamyl transferase levels are associated with metabolic syndrome in community-dwelling individuals. Journal of Atherosclerosis and Thrombosis 2009, 16:355-362.
50. Anty R., Iannelli A., Patouraux S., et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Alimentary Pharmacology and Therapeutics 2010, 32:1315-1322.
51. Xia M.F., Yan H.M., Lin H.D., et al. Elevation of liver enzymes within the normal limits and metabolic syndrome. Clinical and Experimental Pharmacology and Physiology 2011, 38:373-379.
52. Boursier J., Chaigneau J., Roullier V., et al. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD. European Journal of Gastroenterology and Hepatology 2011, 23:974-981.
53. Hu X., Huang Y., Bao Z., et al. Prevalence and factors associated with non-alcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterology 2012, 12:123.
54. Pickhardt P.J., Jee Y., O'Connor S.D., et al. Visceral adiposity and hepatic steatosis at abdominal CT: association with the metabolic syndrome. American Journal of Roentgenology 2012, 198:1100-1107.
55. Castro-Martínez M.G., Banderas-Lares D.Z., Ramírez-Martínez J.C., et al. Prevalence of non-alcoholic fatty liver disease in subjects with metabolic syndrome. Cirugia y Cirujanos 2012, 80:128-133.
56. Kwon Y.M., Oh S.W., Hwang S.S., et al. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. American Journal of Gastroenterology 2012, 107:1852-1858.
57. Sinn D.H., Gwak G.Y., Park H.N., et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. American Journal of Gastroenterology 2012, 107:561-567.
58. Younossi Z.M., Stepanova M., Negro F., et al. Non-alcoholic fatty liver disease in lean individuals in the United States. Medicine 2012, 91:319-327.
59. Yousefzadeh G., Shokoohi M., Yeganeh M., et al. Role of gamma-glutamyl transferase (GGT) in diagnosis of impaired glucose tolerance and metabolic syndrome: a prospective cohort research from the Kerman Coronary Artery Disease Risk Study (KERCADRS). Diabetology & Metabolic Syndrome 2012, 6:190-194.
60. Soresi M., Noto D., Cefalù A.B., et al. Non-alcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetologica 2013, 50:241-249.
61. Smits M.M., Ioannou G.N., Boyko E.J., et al. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. Journal of Gastroenterology and Hepatology 2013, 28:664-670.
62. Eraslan S., Kizilgul M., Uzunlulu M., et al. Frequency of metabolic syndrome and 25-hydroxyvitamin D3 levels in patients with non-alcoholic fatty liver disease. Minerva Medica 2013, 104:447-453.
63. Juárez-Rojas J.G., Medina-Urrutia A.X., Jorge-Galarza E., et al. Fatty liver increases the association of metabolic syndrome with diabetes and atherosclerosis. Diabetes Care 2013, 36:1726-1728.
64. Tao L., Li X., Zhu H., et al. Association between γ-glutamyl transferase and metabolic syndrome: a cross-sectional study of an adult population in Beijing. International Journal of Environmental Research and Public Health 2013, 10:5523-5540.
65. Fraser A., Harris R., Sattar N., et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009, 32:741-750.
66. Lonardo A., Loria P., Leonardi F., et al. Policentrica Steatosi Epatica Non Alcolica. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Disease 2002, 34:204-211.
67. Petta S., Cammà C., Cabibi D., et al. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2011, 34:757-766.
68. Keenan T., Blaha M.J., Nasir K., et al. Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. American Journal of Cardiology 2012, 110:1787-1792.
69. Ryu S., Song J., Choi B.Y., et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Annals of Epidemiology 2007, 17:245-252.
70. Sui X., Church T.S., Meriwether R.A., et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism: Clinical and Experimental 2008, 57:845-852.
71. Lee J.M., Kim H.C., Cho H.M., et al. Association between serum uric acid level and metabolic syndrome. Journal of Preventive Medicine and Public Health 2012, 45:181-187.
72. Zhang Q., Zhang C., Song X., et al. A longitudinal cohort based association study between uric acid level and metabolic syndrome in Chinese Han urban male population. BMC Public Health 2012, 12:419.
73. Wang J.Y., Chen Y.L., Hsu C.H., et al. Predictive value of serum uric acid levels for the diagnosis of metabolic syndrome in adolescents. Journal of Pediatrics 2012, 161. 753-6.e2.
74. Lu W., Song K., Wang Y., et al. Relationship between serum uric acid and metabolic syndrome: an analysis by structural equation modeling. Journal of Clinical Lipidology 2012, 6:159-167.
75. Yang T., Chu C.H., Bai C.H., et al. Uric acid level as a risk marker for metabolic syndrome: a Chinese cohort study. Atherosclerosis 2012, 220:525-531.
76. Zhang Z., Bian L., Choi Y. Serum uric acid: a marker of metabolic syndrome and subclinical atherosclerosis in Korean men. Angiology 2012, 63:420-428.
77. Gonçalves J.P., Oliveira A., Severo M., et al. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine 2012, 4:450-457.
78. Hara S., Tsuji H., Ohmoto Y., et al. High serum uric acid level and low urine pH as predictors of metabolic syndrome: a retrospective cohort study in a Japanese urban population. Metabolism: Clinical and Experimental 2012, 61:281-288.
79. Zhang M.L., Gao Y.X., Wang X., et al. Serum uric acid and appropriate cut-off value for prediction of metabolic syndrome among Chinese adults. Journal of Clinical Biochemistry and Nutrition 2013, 52:38-42.
80. Osgood K., Krakoff J., Thearle M. Serum uric acid predicts both current and future components of the metabolic syndrome. Metabolic Syndrome and Related Disorders 2013, 11:157-162.
81. Ziaee A., Esmailzadehha N., Ghorbani A., et al. Association between uric acid and metabolic syndrome in Qazvin Metabolic Diseases Study (QMDS), Iran. Global Journal of Health Science 2012, 5:155-165.
82. Cohen E., Krause I., Fraser A., et al. Hyperuricemia and metabolic syndrome: lessons from a large cohort from Israel. Israel Medical Association Journal 2012, 14:676-680.
83. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. Journal of Hepatology 2008, 48:993-999.
84. Abdelmalek M.F., Suzuki A., Guy C., et al. Increased fructose consumption is associated with fibrosis severity in patients with non-alcoholic fatty liver disease. Hepatology 2010, 51:1961-1971.
85. Basaranoglu M., Basaranoglu G., Sabuncu T., et al. Fructose as a key player in the development of fatty liver disease. World Journal of Gastroenterology 2013, 19:1166-1172.
86. Dhingra R., Sullivan L., Jacques P.F., et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 2007, 116:480-488.
87. Perez-Pozo S.E., Schold J., Nakagawa T., et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. International Journal of Obesity 2010, 34:454-461.
88. Khitan Z., Kim D.H. Fructose: a key factor in the development of metabolic syndrome and hypertension. Journal of Nutrition and Metabolism 2013, 2013:682673.
89. Liangpunsakul S., Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?. Journal of Clinical Gastroenterology 2003, 37:340-343.
90. Ittermann T., Haring R., Wallaschofski H., et al. Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania. Thyroid 2012, 22:568-574.
91. Chung G.E., Kim D., Kim W., et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. Journal of Hepatology 2012, 57:150-156.
92. Carulli L., Ballestri S., Lonardo A., et al. Is non-alcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?. Internal and Emergency Medicine 2013, 8:297-305.
93. Park H.T., Cho G.J., Ahn K.H., et al. Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas 2009, 62:301-305.
94. Ruhla S., Weickert M.O., Arafat A.M., et al. A high normal TSH is associated with the metabolic syndrome. Clinical Endocrinology 2010, 72:696-701.
95. Lai Y., Wang J., Jiang F., et al. The relationship between serum thyrotropin and components of metabolic syndrome. Endocrine Journal 2011, 58:23-30.
96. Heima N.E., Eekhoff E.M., Oosterwerff M.M., et al. Thyroid function and the metabolic syndrome in older persons: a population-based study. European Journal of Endocrinology/European Federation of Endocrine Societies 2012, 168:59-65.
97. Waring A.C., Rodondi N., Harrison S., et al. Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing and Body Composition Study. Clinical Endocrinology 2012, 76:911.
98. Trauner M., Claudel T., Fickert P., et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Digestive Diseases 2010, 28:220-224.
99. Liechti F., Dufour J.F. Treatment of NASH with ursodeoxycholic acid: cons. Clinics and Research in Hepatology and Gastroenterology 2012, 36:S46-S52.
100. Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clinics and Research in Hepatology and Gastroenterology 2012, 36:S41-S45.
101. Liaset B., Hao Q., Jørgensen H., et al. Nutritional regulation of bile acid metabolism is associated with improved pathological characteristics of the metabolic syndrome. Journal of Biological Chemistry 2011, 286:28382-28395.
102. Watanabe M., Morimoto K., Houten S.M., et al. Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS ONE 2012, 7:e38286.
103. Porez G., Prawitt J., Gross B., et al. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. Journal of Lipid Research 2012, 53:1723-1737.
104. Johnson N.A., George J. Fitness versus fatness: moving beyond weight loss in non-alcoholic fatty liver disease. Hepatology 2010, 52:370-381.
105. Hallsworth K., Fattakhova G., Hollingsworth K.G., et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011, 60:1278-1283.
106. Bae J.C., Suh S., Park S.E., et al. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS ONE 2012, 7:e46819.
107. Keating S.E., Hackett D.A., George J., et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Hepatology 2012, 57:157-166.
108. Gerber L., Otgonsuren M., Mishra A., et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Alimentary Pharmacology and Therapeutics 2012, 36:772-781.
109. Thoma C., Day C.P., Trenell M.I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. Journal of Hepatology 2012, 56:255-266.
110. Murer M., Schmied C., Battegay E., et al. Physical activity behaviour in patients with metabolic syndrome. Swiss Medical Weekly 2012, 142:w13691.
111. Yamaoka K., Tango T. Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Medicine 2012, 10:138.
112. Hagnäs M.P., Cederberg H., Mikkola I., et al. Reduction in metabolic syndrome among obese young men is associated with exercise-induced body composition changes during military service. Diabetes Research and Clinical Practice 2012, 98:312-319.
113. Kim J.W., Kim D.Y. Effects of aerobic exercise training on serum sex hormone binding globulin, body fat index, and metabolic syndrome factors in obese postmenopausal women. Metabolic Syndrome and Related Disorders 2012, 10:452-457.
114. Nanri A., Tomita K., Matsushita Y., et al. Effect of six months lifestyle intervention in Japanese men with metabolic syndrome: randomized controlled trial. Journal of Occupational Health 2012, 54:215-222.
115. Gardner A.W., Parker D.E., Krishnan S., et al. Metabolic syndrome and daily ambulation in children, adolescents, and young adults. Medicine and Science in Sports and Exercise 2013, 45:163-169.
116. Kim J., Tanabe K., Yoshizawa Y., et al. Lifestyle-based physical activity intervention for one year improves metabolic syndrome in overweight male employees. Tohoku Journal of Experimental Medicine 2013, 229:11-17.
117. Dunn W., Xu R., Schwimmer J.B. Modest wine drinking and decreased prevalence of suspected non-alcoholic fatty liver disease. Hepatology 2008, 47:1947-1954.
118. Moriya A., Iwasaki Y., Ohguchi S., et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2011, 33:378-388.
119. Dunn W., Sanyal A.J., Brunt E.M., et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology 2012, 57:384-391.
120. Hamaguchi M., Kojima T., Ohbora A., et al. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World Journal of Gastroenterology 2012, 18:156-167.
121. Carnethon M.R., Loria C.M., Hill J.O., et al. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care 2004, 27:2707-2715.
122. Wilsgaard T., Jacobsen B.K. Lifestyle factors and incident metabolic syndrome. The Tromsø study 1979-2001. Diabetes Research and Clinical Practice 2007, 78:217e24.
123. Baik I., Shin C. Prospective study of alcohol consumption and metabolic syndrome. American Journal of Clinical Nutrition 2008, 87:1455-1463.
124. Alkerwi A., Boutsen M., Vaillant M., et al. Alcohol consumption and the prevalence of metabolic syndrome: a meta-analysis of observational studies. Atherosclerosis 2009, 204:624-635.
125. Baliunas D.O., Taylor B.J., Irving H., et al. Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2009, 32:2123-2132.
126. Wakabayashi I. Cross-sectional relationship between alcohol consumption and prevalence of metabolic syndrome in Japanese men and women. Journal of Atherosclerosis and Thrombosis 2010, 17:695-704.
127. Lee K.W., Park B.J., Kang H.T., et al. Alcohol-drinking patterns and metabolic syndrome risk: the 2007 Korean national health and nutrition examination survey. Alcohol 2011, 45:499-505.
128. Sayon-Orea C., Martinez-Gonzalez M.A., Bes-Rastrollo M. Alcohol consumption and body weight: a systematic review. Nutrition Reviews 2011, 69:419-431.
129. Kim B.J., Kim B.S., Kang J.H. Alcohol consumption and incidence of metabolic syndrome in Korean men. A 3-year follow-up study. Circulation Journal 2012, 76:2363-2371.
130. Chen C.C., Lin W.Y., Li C.I., et al. The association of alcohol consumption with metabolic syndrome and its individual components: the Taichung community health study. Nutrition Research 2012, 32:24-29.
131. Barrio-Lopez M.T., Bes-Rastrollo M., Sayon-Orea C., et al. Different types of alcoholic beverages and incidence of metabolic syndrome and its components in a Mediterranean cohort. Clinical Nutrition 2013, 32:797-804.
132. Stoutenberg M., Lee D.C., Sui X., et al. Prospective study of alcohol consumption and the incidence of the metabolic syndrome in US men. British Journal of Nutrition 2013, 110:901-910.
133. Birerdinc A., Stepanova M., Pawloski L., et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2012, 35:76-82.
134. Molloy J.W., Calcagno C.J., Williams C.D., et al. Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012, 55:429-436.
135. Anty R., Marjoux S., Iannelli A., et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. Journal of Hepatology 2012, 57:1090-1096.
136. Gutiérrez-Grobe Y., Chávez-Tapia N., Sánchez-Valle V., et al. High coffee intake is associated with lower grade non-alcoholic fatty liver disease: the role of peripheral antioxidant activity. Annals of Hepatology 2012, 11:350-355.
137. Masterton G.S., Hayes P.C. Coffee and the liver: a potential treatment for liver disease?. European Journal of Gastroenterology and Hepatology 2010, 22:1277-1283.
138. Kalthoff S., Ehmer U., Freiberg N., et al. Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010, 139:1699-1710.
139. Yamauchi R., Kobayashi M., Matsuda Y., et al. Coffee and caffeine ameliorate hyperglycemia, fatty liver, and inflammatory adipocytokine expression in spontaneously diabetic KK-Ay mice. Journal of Agricultural and Food Chemistry 2010, 58:5597-5603.
140. Matsuda Y., Kobayashi M., Yamauchi R., et al. Coffee and caffeine improve insulin sensitivity and glucose tolerance in C57BL/6J mice fed a high-fat diet. Bioscience, Biotechnology, and Biochemistry 2011, 75:2309-2315.
141. Carrieri M.P., Sogni P., Cohen J., et al. HEPAVIH Study Group. Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13). Hepatology 2012, 56:2010.
142. Sugiura C., Nishimatsu S., Moriyama T., et al. Catechins and caffeine inhibit fat accumulation in mice through the improvement of hepatic lipid metabolism. Journal of Obesity 2012, 2012:520510.
143. Hino A., Adachi H., Enomoto M., et al. Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome: an epidemiological study in a general Japanese population. Diabetes Research and Clinical Practice 2007, 76:383-389.
144. Panchal S.K., Wong W.Y., Kauter K., et al. Caffeine attenuates metabolic syndrome in diet-induced obese rats. Nutrition 2012, 28:1055-1062.
145. Takami H., Nakamoto M., Uemura H., et al. Inverse correlation between coffee consumption and prevalence of metabolic syndrome: baseline survey of the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study in Tokushima, Japan. Journal of Epidemiology 2013, 23:12-20.
146. Hamabe A., Uto H., Imamura Y., et al. Impact of cigarette smoking on onset of non-alcoholic fatty liver disease over a 10-year period. Journal of Gastroenterology 2011, 46:769-778.
147. Zein C.O., Unalp A., Colvin R., et al. Non-alcoholic steatohepatitis clinical research network. Smoking and severity of hepatic fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology 2011, 54:753-759.
148. Koehler E.M., Schouten J.N., Hansen B.E., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. Journal of Hepatology 2012, 57:1305-1311.
149. Sun K., Liu J., Ning G. Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies. PLoS ONE 2012, 7:e47791.
150. Hsieh S.D., Muto T., Murase T., et al. Association of short sleep duration with obesity, diabetes, fatty liver and behavioral factors in Japanese men. Internal Medicine 2011, 50:2499-2502.
151. Aron-Wisnewsky J., Minville C., Tordjman J., et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. Journal of Hepatology 2012, 56:225-233.
152. Musso G., Cassader M., Olivetti C., et al. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obesity Reviews 2013, 14:417-431.
153. Sookoian S., Gemma C., Fernández Gianotti T., et al. Effects of rotating shift work on biomarkers of metabolic syndrome and inflammation. Journal of Internal Medicine 2007, 261:285-292.
154. Donga E., van Dijk M., van Dijk J.G., et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2010, 95:2963-2968.
155. Choi J.K., Kim M.Y., Kim J.K., et al. Association between short sleep duration and high incidence of metabolic syndrome in midlife women. Tohoku Journal of Experimental Medicine 2011, 225:187-193.
156. Arora T., Jiang C.Q., Thomas G.N., et al. Self-reported long total sleep duration is associated with metabolic syndrome: the Guangzhou Biobank Cohort Study. Diabetes Care 2011, 34:2317-2319.
157. Yilmaz Y., Ones T., Purnak T., et al. Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans. Alimentary Pharmacology and Therapeutics 2011, 34:318-323.
158. van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M., et al. Cold-activated brown adipose tissue in healthy men. New England Journal of Medicine 2009, 360:1500-1508.
159. Cypess A.M., Lehman S., Williams G., et al. Identification and importance of brown adipose tissue in adult humans. New England Journal of Medicine 2009, 360:1509-1517.
160. Pasanisi F., Pace L., Fonti R., et al. Evidence of brown fat activity in constitutional leanness. Journal of Clinical Endocrinology and Metabolism 2013, 98:1214-1218.
161. Matsen M.E., Thaler J.P., Wisse B.E., et al. In uncontrolled diabetes, thyroid hormone and sympathetic activators induce thermogenesis without increasing glucose uptake in brown adipose tissue. American Journal of Physiology: Endocrinology and Metabolism 2013, 304:E734-E746.
162. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
163. Nair S., Cope K., Risby T.H., et al. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of non-alcoholic steatohepatitis. American Journal of Gastroenterology 2001, 96:1200-1204.
164. Thuy S., Ladurner R., Volynets V., et al. Non-alcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. Journal of Nutrition 2008, 138:1452-1455.
165. Miele L., Valenza V., La Torre G., et al. Increased intestinal permeability and tight junction alterations in non-alcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
166. Harte A.L., da Silva N.F., Creely S.J., et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. Journal of Inflammation 2010, 7:15.
167. Verdam F.J., Rensen S.S., Driessen A., et al. Novel evidence for chronic exposure to endotoxin in human non-alcoholic steatohepatitis. Journal of Clinical Gastroenterology 2011, 45:149-152.
168. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
169. Machado M.V., Cortez-Pinto H. Gut microbiota and non-alcoholic fatty liver disease. Annals of Hepatology 2012, 11:440-449.
170. Tremaroli V., Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489:242-249.
171. Zhu L., Baker S.S., Gill C., et al. Characterization of gut microbiomes in non-alcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57:601-609.
172. Aron-Wisnewsky J., Gaborit B., Dutour A., et al. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clinical Microbiology and Infection 2013, 19:338-348.
173. Ley R.E., Bäckhed F., Turnbaugh P., et al. Obesity alters gut microbial ecology. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:11070-11075.
174. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
175. Ley R.E., Turnbaugh P.J., Klein S., et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
176. Turnbaugh P.J., Hamady M., Yatsunenko T., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
177. Schwiertz A., Taras D., Schäfer K., et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010, 18:190-195.
178. Cani P.D., Possemiers S., Van de Wiele T., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
179. Furet J.P., Kong L.C., Tap J., et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010, 59:3049-3057.
180. Vijay-Kumar M., Aitken J.D., Carvalho F.A., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
181. Tilg H., Kaser A. Gut microbiome, obesity, and metabolic dysfunction. Journal of Clinical Investigation 2011, 121:2126-2132.
182. Greenblum S., Turnbaugh P.J., Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:594-599.
183. Leber B., Tripolt N.J., Blattl D., et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study. European Journal of Clinical Nutrition 2012, 66:1110-1115.
184. Tehrani A.B., Nezami B.G., Gewirtz A., et al. Obesity and its associated disease: a role for microbiota?. Neurogastroenterology and Motility 2012, 24:305-311.
185. Zupancic M.L., Cantarel B.L., Liu Z., et al. Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndrome. PLoS ONE 2012, 7:e43052.
186. Vrieze A., Van Nood E., Holleman F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916.
187. Parnell J.A., Reimer R.A. Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats. British Journal of Nutrition 2012, 107:601-613.
188. Caricilli A.M., Saad M.J. The role of gut microbiota on insulin resistance. Nutrients 2013, 5:829-851.
189. Targher G., Bertolini L., Scala L., et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases 2007, 17:517-524.
190. Barchetta I., Carotti S., Labbadia G., et al. Liver vitamin D receptor. CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with non-alcoholic steatohepatitis or hepatitis C virus. Hepatology 2012, 56:2180-2187.
191. Eliades M., Spyrou E., Agrawal N., et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2013, 38:246-254.
192. Adams L.A., White S.W., Marsh J.A., et al. Association between liver-specific gene polymorphisms and their expression levels with non-alcoholic fatty liver disease. Hepatology 2013, 57:590-600.
193. Kayaniyil S., Retnakaran R., Harris S.B., et al. Prospective associations of vitamin D with b-cell function and glycemia. Diabetes 2011, 60:2947-2953.
194. Ding C., Gao D., Wilding J., et al. Vitamin D signalling in adipose tissue. British Journal of Nutrition 2012, 108:1915-1923.
195. Maki K.C., Fulgoni V.L., Keast D.R., et al. Vitamin D intake and status are associated with lower prevalence of metabolic syndrome in U.S. adults: National Health and Nutrition Examination Surveys 2003-2006. Metabolic Syndrome and Related Disorders 2012, 10:363-372.
196. Wang C. Role of vitamin D in cardiometabolic diseases. Journal of Diabetes Research 2013, 243934.
197. Khan H., Kunutsor S., Franco O.H., et al. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proceedings of the Nutrition Society 2013, 72:89-97.
198. Kayaniyil S., Harris S.B., Retnakaran R., et al. Prospective association of 25(OH)D with metabolic syndrome. Clinical Endocrinology 2014, 80:502-507.
199. Tsatsoulis A., Mantzaris M.D., Bellou S., et al. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment - an evolutionary perspective. Metabolism: Clinical and Experimental 2012, 62:622-633.
200. Leclercq I.A., Da Silva Morais A., Schroyen B., et al. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. Journal of Hepatology 2007, 47:142-156.
201. Seki E., Brenner D.A., Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012, 143:307-320.
202. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
203. Reaven G.M. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
204. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
205. Loria P., Lonardo A., Carulli N. Should non-alcoholic fatty liver disease be renamed?. Digestive Diseases 2005, 23:72-82.
206. Hamaguchi M., Takeda N., Kojima T., et al. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World Journal of Gastroenterology 2012, 18:1508-1516.
207. Lonardo A., Bellentani S., Ratziu V., et al. Insulin resistance in non-alcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?. Expert Review of Gastroenterology & Hepatology 2011, 5:279-289.
208. Suzuki A., Angulo P., Lymp J., et al. Chronological development of elevated aminotransferases in a non-alcoholic population. Hepatology 2005, 41:64-71.
209. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42:987-1000.
210. Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:27-38.
211. Yamaguchi K., Yang L., McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with non-alcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
212. Lonardo A., Loria P., Carulli N. Insulin resistance in non-alcoholic fatty liver disease: a clinical perspective. Falk symposium 121 steatohepatitis (NASH and ASH) 2001, 104-113. Kluwer, Dordrecht, The Netherlands. U. Leuschner, O. James, H. Dancygier (Eds.).
213. Caldwell S.H., Ikura Y., Iezzoni J.C., et al. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?. Journal of Gastroenterology and Hepatology 2007, 22:S11-S19.
214. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
215. Riva M.A., Riva E., Spicci M., et al. The city of "Hepar": rituals, gastronomy, and politics at the origins of the modern names for the liver. Journal of Hepatology 2011, 55:1132-1136.
216. Kumashiro N., Erion D.M., Zhang D., et al. Cellular mechanism of insulin resistance in non-alcoholic fatty liver disease. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:16381-16385.
217. Samuel V.T., Liu Z.X., Wang A., et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in non-alcoholic fatty liver disease. Journal of Clinical Investigation 2007, 117:739-745.
218. Cantley J.L., Yoshimura T., Camporez J.P., et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:1869-1874.
219. Perry R.J., Samuel V.T., Petersen K.F., et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014, 510:84-91.
220. Zammit V.A. Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia. Biochemical Journal 2013, 451:1-12.
221. Kasturiratne A., Weerasinghe S., Dassanayake A.S., et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. Journal of Gastroenterology and Hepatology 2013, 28:142-147.
222. Ryan M.C., Wilson A.M., Slavin J., et al. Associations between liver histology and severity of the metabolic syndrome in subjects with non-alcoholic fatty liver disease. Diabetes Care 2005, 28:1222-1224.
223. Loria P., Adinolfi L.E., Bellentani S., et al. Practice guidelines for the diagnosis and management of non-alcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Digestive and Liver Disease 2010, 42:272-282.
224. Smits M.M., van Geenen E.J. The clinical significance of pancreatic steatosis. Nature Reviews Gastroenterology & Hepatology 2011, 8:169-177.
225. Straub B.K., Stoeffel P., Heid H., et al. Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology 2008, 47:1936-1946.
226. Wanless I.R., Shiota K. The pathogenesis of non-alcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Seminars in Liver Disease 2004, 24:99-106.
227. Greenberg A.S., Coleman R.A., Kraemer F.B., et al. The role of lipid droplets in metabolic disease in rodents and humans. Journal of Clinical Investigation 2011, 121:2102-2110.
228. Lonardo A., Lombardini S., Scaglioni F., et al. Hepatic steatosis and insulin resistance: does etiology make a difference?. Journal of Hepatology 2006, 44:190-196.
229. Amaro A., Fabbrini E., Kars M., et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010, 139:149-153.
230. Ballestri S., Lonardo A., Losi L., et al. Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?. Internal and Emergency Medicine 2009, 4:71-73.
231. Kantartzis K., Machicao F., Machann J., et al. The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clinical Science (London) 2009, 116:531-537.
232. Kantartzis K., Peter A., Machicao F., et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009, 58:2616-2623.
233. Shen J., Wong G.L., Chan H.L., et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Alimentary Pharmacology and Therapeutics 2014, 39:532-539.
234. Sun Z., Lazar M.A. Dissociating fatty liver and diabetes. Trends in Endocrinology and Metabolism 2013, 24:4-12.